Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving.

ABSTRACT:

Introduction

Negative reinforcement models posit that relapse to cigarette smoking is driven in part by changes in affect and craving during the quit attempt. Varenicline may aid cessation by attenuating these changes; however, this mediational pathway has not been formally evaluated in placebo-controlled trials. Thus, trajectories of negative affect (NA), positive affect (PA), and craving were tested as mediators of the effect of varenicline on smoking cessation.

Aims and methods

Secondary data analysis was conducted on 828 adults assigned to either varenicline or placebo in a randomized controlled trial for smoking cessation (NCT01314001). Self-reported NA, PA, and craving were assessed 1-week pre-quit, on the target quit day (TQD), and 1 and 4 weeks post-TQD.

Results</

SUBMITTER: Tonkin SS 

PROVIDER: S-EPMC9596996 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature